Skip to content

Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor
Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL
Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL
Partnership expands access to CLL treatment in low-, middle-income countries
Phase 1 data reported for anti-CD123 CAR T-cell therapy in relapsed or refractory AML, BPDCN

Insider Reader Survey

Join SOHO

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Cellular Therapy

AACR 2026 Cellular Therapy Multiple Myeloma News

In vivo CAR-T shows promise but safety is a concern

by Leah Sherwood
April 30, 2026
0 Comments

AACR 2026 Cellular Therapy Leukemia Acute Lymphoblastic Leukemia Lymphoma Aggressive B-Cell Lymphomas Meetings / Conferences Multiple Myeloma Myelodysplastic Syndromes News

NCI director says institute is ‘stable’ after turbulent year

by Leah Sherwood
April 21, 2026
0 Comments

AACR 2026 Cellular Therapy Leukemia Lymphoma Meetings / Conferences Multiple Myeloma Myelodysplastic Syndromes News

Former FDA-OCE Director Richard Pazdur: ‘there is a palpable sense of anxiety at FDA’

by Leah Sherwood
April 17, 2026
0 Comments

AACR 2026 Cellular Therapy Leukemia Lymphoma Meetings / Conferences News

Clinical care still needs human intelligence in the AI era

by Leah Sherwood
April 16, 2026
0 Comments

Cellular Therapy Multiple Myeloma News

Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM

by SOHO Insider Editors
April 6, 2026
0 Comments

Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas

CAR-T improves survival, reduces hospital use in R/R LBCL

by SOHO Insider Editors
April 3, 2026
0 Comments

Cellular Therapy Leukemia Chronic Lymphocytic Leukemia News

Sustaining momentum in R/R CLL/SLL care: a five-month follow-up

by sohonews
April 2, 2026
0 Comments

Community Oncology News Community Oncology Cellular Therapy Multiple Myeloma Video Interviews

Dr. Jeffrey Matous on managing access to novel agents in the community setting

by SOHO Insider Editors
March 30, 2026
0 Comments

Past Sessions Community Oncology Cellular Therapy Lymphoma News Video Interviews

Dr. Tara Graff presents Implementing bispecific antibodies in community practice

by SOHO Insider Editors
March 30, 2026
0 Comments

Tandem Meetings 2026 Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Meetings / Conferences News

Interim phase 2 analysis shows zamto-cel activity in DLBCL

by Leah Sherwood
March 19, 2026
0 Comments

1
2
3
4
...
8

Top Categories

Cellular Therapy

79

Leukemia

126

Lymphoma

140

Multiple Myeloma

118

Myelodysplastic Syndromes

44

Myeloproliferative Neoplasms

35

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Cellular Therapy

In vivo CAR-T shows promise but safety is a concern

NCI director says institute is ‘stable’ after turbulent year

Former FDA-OCE Director Richard Pazdur: ‘there is a palpable sense of anxiety at FDA’

Clinical care still needs human intelligence in the AI era

Japan’s PMDA clears phase 3 trial of eque-cel in relapsed or refractory MM

CAR-T improves survival, reduces hospital use in R/R LBCL

Sustaining momentum in R/R CLL/SLL care: a five-month follow-up

Dr. Jeffrey Matous on managing access to novel agents in the community setting

Dr. Tara Graff presents Implementing bispecific antibodies in community practice

Interim phase 2 analysis shows zamto-cel activity in DLBCL

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Recent Posts

Chemotherapy-free ATO/ATRA regimen improves survival in APL, but patient age is a crucial factor

Dr. Ying Huang presents first-in-human data for in vivo CAR-T LB2501 in B-cell NHL

Liso-cel plus ibrutinib induces deep remissions in patients with relapsed or refractory CLL/SLL

About Us

Categories

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Contact Info

Follow Us

Cellular Therapy

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Cellular Therapy

Leukemia

Lymphoma

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms